Vaxart (traded under the ticker symbol VXRT) maintains its official listing status on the Nasdaq Capital Market, where its equity shares continue to be bought and sold by public market participants. Like many small-cap clinical-stage biotechnology companies trading on major exchanges, Vaxart must continuously monitor and comply with Nasdaq's strict listing maintenance standards, including minimum bid price requirements and market capitalization thresholds. Should share prices drift downward over extended periods, companies occasionally receive compliance deficiency notices, but Vaxart remains actively listed on the exchange while pursuing its clinical development pipeline.